Latest Breast cancer treatment Stories

Dune Medical Devices Receives FDA Approval for Breakthrough Advancement in Breast Cancer Surgery

2013-01-02 08:23:21

BOSTON, Jan. 2, 2013 /PRNewswire/ -- Dune Medical Devices, Inc., announced today that its breakthrough intra-operative tissue assessment tool for early-stage breast cancer surgery, the MarginProbe System, has received Premarket Approval (PMA) by the United States Food and Drug Administration. The technology significantly improves surgeons' ability to intra-operatively identify "cancer on the margin" and significantly reduce pathologically positive margins following a patient's...

Milk Protein Found In Breast Cells Triggers Aggressive Cancer

2012-12-28 12:38:27

Lawrence LeBlond for redOrbit.com - Your Universe Online Health advocates for years have told us that milk does the body good. Health experts have also been keen on promoting the positive effects breastfed milk has on childhood development. But now, milk is getting a bad rap--particularly, a certain protein found in breast milk is the problem. Scientists have recently discovered that this protein, called ELF5, which is found in all breast cells and is responsible for milk production, is...

Expensive Proton Beam Therapy No Better Than Traditional Treatment For Prostate Cancer

2012-12-28 11:30:22

Lawrence LeBlond for redOrbit.com - Your Universe Online A new study published this week in the Journal of the National Cancer Institute has found that an expensive prostate cancer radiation treatment provided no long-term benefit over traditional radiation. The treatment, known as proton beam therapy, uses atomic particles to treat cancer and is said to target tumors more precisely than traditional methods. However the method has been found to produce no fewer side effects than much...

New Category I CPT Codes and Payment Rates for Circulating Tumor Cell Testing Effective January 1

2012-12-27 08:24:38

RARITAN, N.J., Dec. 27, 2012 /PRNewswire/ -- Veridex, LLC today announced that new Category I Current Procedural Technology (CPT) codes for circulating tumor cell (CTC) testing will go into effect in the United States on January 1, 2013. CPT codes are assigned by the American Medical Association (AMA) to medical, surgical, and diagnostic services to communicate uniform information about medical services and procedures among physicians, patients, payers and others for...

CellSearch® 'Liquid Biopsy' Approved for Breast Cancer Patients in China

2012-12-12 20:21:34

RARITAN, N.J., Dec. 12, 2012 /PRNewswire/ -- Veridex, LLC today announced approval from the China State Food & Drug Administration (SFDA) for the CellSearch(®) circulating tumor cell (CTC) test as an in vitro diagnostic for women with metastatic breast cancer. This makes CellSearch(®) the first and only approved CTC test for cancer patients in China, which is the seventh country outside of the United States and European Union to clear CellSearch(®) for use as an aid in the...

Vaccine offers promise as post-surgery treatment for pancreatic cancer patients

2012-12-11 16:24:17

WINSTON-SALEM, N.C., Dec. 11, 2012 /PRNewswire-USNewswire/ -- When Teresa Thorn started getting nausea last February, she thought it was an ulcer, something she'd had years earlier. As the days went on, though, the nausea remained and Thorn's color started changing, something her co-workers noticed. Finally one Sunday, she and her mother, Naomi Ivester, went to the Emergency Department at Wake Forest Baptist Medical Center, where a battery of tests began. Her longtime physician at...

Genomic Health Announces Results from Six Studies Demonstrating Unique Value of the Oncotype DX Breast Cancer Test in Early Stage Breast Cancer

2012-12-10 08:25:43

REDWOOD CITY, Calif., Dec. 10, 2012 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the results from six studies of the Oncotype® DX breast cancer test presented at the 34(th) Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) reinforcing the impact of the test on facilitating better informed treatment decisions in patients with node-negative and node-positive invasive early-stage breast cancer. Additionally, two studies demonstrated the test's cost...

Roche's Perjeta significantly extends survival in people with HER2-positive metastatic breast cancer

2012-12-10 08:25:23

MISSISSAUGA, ON, Dec. 10, 2012 /CNW/ - Roche today announced updated survival results from the Phase III CLEOPATRA study, which showed that the combination of Perjeta® (pertuzumab), Herceptin® (trastuzumab) and docetaxel chemotherapy significantly extended the lives (overall survival) of people with previously untreated HER2-positive metastatic breast cancer (mBC), compared to Herceptin, chemotherapy and placebo. Results showed that the risk of death was reduced by 34 percent...

Cell Therapeutics Reports on Cooperative Group Sponsored Trial of Brostallicin in Patients with Metastatic Triple-Negative Breast Cancer

2012-12-05 20:20:54

SEATTLE, Dec. 5, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported on interim results from a cooperative group sponsored Phase 2 clinical trial of brostallicin in combination with cisplatin for the treatment of women with metastatic triple-negative breast cancer that were presented at the San Antonio Breast Cancer Symposium (SABCS) held from December 4-8, 2012. The study enrolled women with confirmed measurable metastatic disease and triple...

Researchers Shed New Light For Setback-Dogged Cancer Treatment

2012-11-27 11:25:29

Several drugs companies have ineffectively tried to produce antibodies that bind to the IGF-1 receptor on the cell surface, which has a critical part to play in the development of cancer. Scientists at Karolinska Institutet in Sweden have now ascertained how these antibodies work, and can explain why only some cancer patients are helped by IGF-1 blockers during clinical tests. The researchers also present a means by which drugs of this kind could help more cancer patients. Every cell...